Yes, medical marijuana is a controlled substance under federal law. It is classified as Schedule I under the Controlled Substances Act, the most restrictive category, alongside heroin and LSD. This classification has remained in place since 1970, though a rescheduling process is currently underway that could move it to Schedule III.
That Schedule I status creates a unique legal situation: the federal government officially considers marijuana a drug with “no currently accepted medical use and a high potential for abuse,” yet the majority of states have passed laws allowing patients to use it for medical purposes. Understanding how this contradiction works in practice matters if you hold a medical marijuana card or are considering getting one.
What Schedule I Means
The DEA classifies drugs into five schedules based on their potential for abuse and whether they have an accepted medical use. Schedule I is reserved for substances the federal government considers both highly prone to abuse and lacking any recognized medical application. Schedule II includes drugs like oxycodone and fentanyl, which carry high abuse potential but have approved medical uses. Schedule III covers drugs with moderate abuse potential, such as testosterone and ketamine.
Marijuana’s placement in Schedule I has far-reaching consequences. It makes the drug illegal to prescribe, possess, or distribute under federal law regardless of what your state allows. It also creates significant barriers for researchers who want to study its medical effects, since Schedule I research requires a site-specific DEA investigator registration and additional layers of federal approval that don’t apply to drugs in lower schedules.
Why Doctors Write “Recommendations,” Not Prescriptions
If you’ve visited a medical marijuana doctor, you may have noticed they gave you a recommendation rather than a prescription. This distinction is not just semantics. Because marijuana sits in Schedule I, no doctor can legally prescribe it. Prescriptions are reserved for FDA-approved drugs, and the FDA has not approved marijuana itself as a medicine.
Instead, physicians in states with medical marijuana programs write a recommendation stating that you could benefit from cannabis. You then register with your state’s database, receive a patient ID card, and purchase marijuana from a licensed dispensary. None of the standard safeguards that come with FDA-approved drugs apply here: there are no package inserts with dosing guidelines, no published clinical results from the rigorous approval process, and no official information about expected side effects. Your state program and dispensary staff fill some of that gap, but the experience is fundamentally different from picking up a prescription at a pharmacy.
FDA-Approved Cannabis Medications
While marijuana itself remains unapproved, the FDA has cleared four cannabis-related medications. These occupy a different legal space than the flower or edibles you’d buy at a dispensary.
- Epidiolex is the only drug derived directly from the cannabis plant. It contains purified CBD and is approved to treat seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients two years and older. Because it contains less than 0.3% THC, it was removed from the controlled substances schedules entirely.
- Marinol and Syndros both contain a synthetic version of THC. They’re approved for nausea from cancer chemotherapy and appetite loss in AIDS patients. These are placed in Schedule II or III depending on the formulation.
- Cesamet contains a synthetic compound chemically similar to THC, also approved for chemotherapy-related nausea.
These drugs go through the same testing and approval process as any other medication. They come with dosing instructions, known side effects, and established indications. They can be prescribed like any other controlled substance in their schedule. The gap between these approved products and dispensary marijuana illustrates why the federal government treats them so differently.
How State Programs Operate Despite Federal Law
The reason state medical marijuana programs can function at all comes down to a federal spending provision known as the Rohrabacher-Farr Amendment. First passed in December 2014, this provision prohibits the Department of Justice from using any of its allocated funds to prevent states from implementing their own medical marijuana laws. It covers the use, distribution, possession, and cultivation of medical marijuana in states that have legalized it.
This is not the same as legalization. Congress has renewed the amendment each year as part of its spending bills, most recently in 2022. But it’s a funding restriction, not a change to the Controlled Substances Act. If Congress chose not to renew it, the legal protection would disappear. And federal agencies outside the DOJ are not bound by it, which is why federal employers and federally regulated industries can still enforce marijuana-free workplace policies.
The Rescheduling Process
A formal effort to move marijuana from Schedule I to Schedule III has been in progress since October 2022, when President Biden asked the Department of Health and Human Services and the DEA to review marijuana’s scheduling. In August 2023, HHS recommended reclassification to Schedule III, a recommendation supported by the National Institute on Drug Abuse and the FDA. The DEA proposed a rule to make that move in May 2024.
The proposal received nearly 43,000 public comments, and in August 2024, the DEA announced it would hold a formal hearing. That hearing was scheduled for January 21, 2025, but was postponed due to a legal appeal. In December 2025, President Trump issued an executive order instructing the attorney general to expedite the rescheduling process. The rulemaking remains ongoing, awaiting the hearing.
If marijuana does move to Schedule III, it would remain a controlled substance, just a less restricted one. The practical changes would be significant: researchers would face fewer barriers to studying it, cannabis businesses could access standard banking services and federal tax deductions currently denied to them, and the legal conflict between federal and state law would narrow considerably. It would not, however, make recreational use legal at the federal level.
How Controlled Status Affects You Practically
Even with a valid state medical marijuana card, the federal Schedule I classification creates real consequences in certain areas of your life. The most immediate is employment. The U.S. Department of Transportation has stated explicitly that marijuana remains unacceptable for any safety-sensitive employee subject to federal drug testing, regardless of state law or any pending rescheduling. This applies to truck drivers, airline pilots, train operators, and other transportation workers. Many private employers in non-regulated industries also maintain marijuana-free policies, and federal law gives them legal cover to do so even in states where medical use is protected.
Housing is another pressure point. Federally subsidized housing programs can deny applicants or evict tenants for marijuana use, since it violates federal law. Gun ownership is also affected: federal firearms forms ask whether you are an “unlawful user of, or addicted to, marijuana or any depressant, stimulant, narcotic drug, or any other controlled substance,” and answering yes (or lying) carries legal consequences.
Hemp vs. Marijuana
The 2018 Farm Bill drew a legal line within the cannabis plant itself. Hemp is defined as any part of the cannabis plant containing no more than 0.3% delta-9 THC on a dry-weight basis. Anything above that threshold is legally marijuana and falls under the Controlled Substances Act. This is why CBD products derived from hemp are widely sold while marijuana remains federally controlled. The chemical difference between the two can be vanishingly small, but the legal difference is enormous.